Legionellosis (LD) becomes a major public health problem, predominantly presenting as Pontiac fever or pneumonia with predominance of Legionella pneumophila (Lp) throughout the world, as reported in a comprehensive recent update [1]. In New Zealand there is a more systematic use of Legionella polymerase chain reaction (PCR) screening, and some clusters of Legionella longbeachae infections (often resistant to tetracyclines) are seen in spring‒summer. We appreciate the comments by Pairman et al. [2] who report the estimated mortality rates assessing only the monotherapy cohort from the report by Cecchini et al.
